Benjamin J. Samelson‐Jones

2.1k citations

33 papers · 862 indexed · h-index 15

Co-authors: Valder R. Arruda Lindsey A. George Bhavya S. Doshi Katherine A. High John E.J. Rasko Margaret V. Ragni Xavier M. Anguela Klaudia Kuranda
Topics: Virus-based gene therapy research (19 papers)Hemophilia Treatment and Research (19 papers)CAR-T cell therapy research (11 papers)
Cited by: Hematology Genetics Oncology
Journals: New England Journal of Medicine Blood PEDIATRICS
Partner nations: United States Australia Canada

In The Last Decade

Benjamin J. Samelson‐Jones

31 papers receiving 848 citations

Peers

Countries citing papers authored by Benjamin J. Samelson‐Jones

Since Specialization

Citations

This map shows the geographic impact of Benjamin J. Samelson‐Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin J. Samelson‐Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin J. Samelson‐Jones more than expected).

Fields of papers citing papers by Benjamin J. Samelson‐Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin J. Samelson‐Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin J. Samelson‐Jones. The network helps show where Benjamin J. Samelson‐Jones may publish in the future.

Co-authorship network of co-authors of Benjamin J. Samelson‐Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin J. Samelson‐Jones. A scholar is included among the top collaborators of Benjamin J. Samelson‐Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin J. Samelson‐Jones. Benjamin J. Samelson‐Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies 2025 ·Molecular Therapy ·Bhavya S. Doshi,(unknown),(unknown),(unknown),Robert J. Davidson,(unknown),Wei Wang,(unknown),(unknown),Benjamin J. Samelson‐Jones,Juliana C. Small,Vijay Bhoj,Lindsey A. George	2
2	Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns 2025 ·Molecular Therapy ·(unknown),Juliana C. Small,(unknown),Sarah McCague,(unknown),Sabrina W. Yum,(unknown),John F. Brandsema,(unknown),Kathleen M. Loomes,Kimberly Y. Lin,(unknown),Oscar H. Mayer,(unknown),(unknown),Benjamin J. Samelson‐Jones,(unknown),Lindsey A. George	0
3	Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study 2025 ·New England Journal of Medicine ·John E.J. Rasko,Benjamin J. Samelson‐Jones,Lindsey A. George,Adam Giermasz,Jonathan M. Ducore,Jerome Teitel,Catherine McGuinn,(unknown),Ype P. de Jong,Amit Chhabra,(unknown),Lynne M. Smith,Ian Winburn,Jeremy Rupon	5
4	A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency 2024 ·International Journal of Molecular Sciences ·Sarina Levy‐Mendelovich,Einat Avishai,Benjamin J. Samelson‐Jones,Rima Dardik,Tami Brutman‐Barazani,Yael Nisgav,Tami Livnat,Gili Kenet	0
5	Coagulation factor VIII: biological basis of emerging hemophilia A therapies 2024 ·Blood ·Benjamin J. Samelson‐Jones,Bhavya S. Doshi,Lindsey A. George	4
6	AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life 2024 ·Molecular Therapy — Methods & Clinical Development ·Bhavya S. Doshi,Benjamin J. Samelson‐Jones,Timothy C. Nichols,Elizabeth P. Merricks,(unknown),(unknown),Benjamin Lee,Valder R. Arruda,Mary Beth Callan	7
7	A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment? 2023 ·Journal of Thrombosis and Haemostasis ·Leonard A. Valentino,Margareth C. Ozelo,Roland W. Herzog,Nigel S. Key,Allyson M. Pishko,Margaret V. Ragni,Benjamin J. Samelson‐Jones,David Lillicrap	11
8	Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog 2023 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Bhavya S. Doshi,Elinor Willis,Timothy C. Nichols,Emma Cook,J.K. Everett,Elizabeth P. Merricks,Valder R. Arruda,Frederic D. Bushman,Mary Beth Callan,Benjamin J. Samelson‐Jones	5
9	Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011 2022 ·Blood ·Stacy E. Croteau,M. Elaine Eyster,Huyen Tran,Margaret V. Ragni,Benjamin J. Samelson‐Jones,Lindsey A. George,Spencer K. Sullivan,John E.J. Rasko,Jill Moormeier,Pantep Angchaisuksiri,Jerome Teitel,Gili Kenet,Tung Wynn,(unknown),Amy MacDougall,(unknown),Trupti Trivedi,Federico Mingozzi,Tiffany Chang,Gallia G. Levy	5
10	Appendix to the Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions: Pediatric Considerations 2022 ·Journal of Vascular and Interventional Radiology ·Horacio M. Padua,Anne Marie Cahill,(unknown),(unknown),Kamlesh Kukreja,Riten Kumar,Francis E. Marshalleck,(unknown),Sheena Patel,Benjamin J. Samelson‐Jones,Raja Shaikh	3
11	Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua 2021 ·Journal of Thrombosis and Haemostasis ·Mary Robinson,Lindsey A. George,Marcus E. Carr,Benjamin J. Samelson‐Jones,Valder R. Arruda,John E. Murphy,Denis Rybin,Jeremy Rupon,Katherine A. High,Stefan Tiefenbacher	22
12	Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A 2020 ·Frontiers in Immunology ·Benjamin J. Samelson‐Jones,Valder R. Arruda	30
13	Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B 2020 ·Molecular Therapy ·Lindsey A. George,Margaret V. Ragni,John E.J. Rasko,Leslie Raffini,Benjamin J. Samelson‐Jones,Margareth C. Ozelo,(unknown),(unknown),Jennifer Wellman,(unknown),Yifeng Chen,Xavier M. Anguela,Klaudia Kuranda,Federico Mingozzi,Katherine A. High	149
14	Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates 2020 ·Molecular Therapy — Methods & Clinical Development ·Benjamin J. Samelson‐Jones,Jonathan D. Finn,Patrícia Favaro,J. Fraser Wright,Valder R. Arruda	38
15	Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity 2019 ·JCI Insight ·Benjamin J. Samelson‐Jones,Jonathan D. Finn,Lindsey A. George,Rodney M. Camire,Valder R. Arruda	35
16	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa 2018 ·Thrombosis Research ·(unknown),(unknown),(unknown),Benjamin J. Samelson‐Jones,(unknown),Elena Campello,(unknown),Valder R. Arruda,Paolo Simioni,Rinku Majumder	6
17	Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy 2018 ·Molecular Therapy — Methods & Clinical Development ·Benjamin J. Samelson‐Jones,Valder R. Arruda	42
18	MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia 2017 ·Pediatric Blood & Cancer ·Benjamin J. Samelson‐Jones,Paula M. Kramer,Michael C. Chicka,William T. Gunning,Michele P. Lambert	2
19	Novel approaches to hemophilia therapy: successes and challenges 2017 ·Blood ·Valder R. Arruda,Bhavya S. Doshi,Benjamin J. Samelson‐Jones	92
20	Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models 2016 ·JCI Insight ·(unknown),Benjamin J. Samelson‐Jones,Julie M. Crudele,(unknown),Benjamin J. Lee,(unknown),Elizabeth P. Merricks,Robin A. Raymer,Timothy C. Nichols,Rodney M. Camire,Valder R. Arruda	30

About Benjamin J. Samelson‐Jones

Benjamin J. Samelson‐Jones is a scholar working on Hematology, Genetics and Oncology, having authored 33 papers that have together received 862 indexed citations. Recurring topics across this work include Virus-based gene therapy research (19 papers), Hemophilia Treatment and Research (19 papers) and CAR-T cell therapy research (11 papers). The work is most often cited by research in Hematology (393 citations), Genetics (498 citations) and Oncology (328 citations). Benjamin J. Samelson‐Jones has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Valder R. Arruda, Lindsey A. George, Bhavya S. Doshi, Katherine A. High, John E.J. Rasko, Margaret V. Ragni, Xavier M. Anguela, Klaudia Kuranda, Federico Mingozzi and Jonathan D. Finn. Their work appears in journals such as New England Journal of Medicine, Blood and PEDIATRICS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact